Skip to main content

-

IJCI-2014-22403

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Juan de la Cierva Incorporación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets

  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Jauset González, Toni
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Serrano del Pozo, Erika|||0000-0003-2417-1499
  • Martín-Fernández, Génesis|||0000-0002-1052-9763
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Brown-Swigart, Lamorna|||0000-0003-2076-5177
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Madan, Babita
  • Virshup, David M.|||0000-0001-6976-850X
  • Evan, Gerard I|||0000-0003-0412-1216
  • Soucek, Laura|||0000-0002-4750-7971
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. Here, we describe how only the lack of the receptor Fzd9, previously identified as a Myc transcriptional target, impairs sustained tumor expansion and β-cell dedifferentiation in a mouse model of Myc-driven insulinoma, allows pancreatic islets to maintain their physiological structure and affects Myc-related global gene expression. Importantly, Wnt signaling inhibition in Fzd9-competent mice largely recapitulates the suppression of proliferation caused by Fzd9 deficiency upon Myc activation. Together, our results indicate that the Wnt signaling receptor Fzd9 is essential for Myc-induced tumorigenesis in pancreatic islets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Jauset, Toni|||0000-0003-2869-5804
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Martín-Fernández, Génesis|||0000-0002-1052-9763
  • Serrano del Pozo, Erika|||0000-0003-2417-1499
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Grueso, Judit|||0000-0003-1093-7940
  • Nonell, Lara|||0000-0002-8538-8213
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.